REYON Pharmaceutical Balance Sheet Health
Financial Health criteria checks 1/6
REYON Pharmaceutical has a total shareholder equity of ₩248.6B and total debt of ₩221.7B, which brings its debt-to-equity ratio to 89.2%. Its total assets and total liabilities are ₩499.8B and ₩251.2B respectively. REYON Pharmaceutical's EBIT is ₩1.8B making its interest coverage ratio -2.9. It has cash and short-term investments of ₩24.2B.
Key information
89.2%
Debt to equity ratio
₩221.66b
Debt
| Interest coverage ratio | -2.9x |
| Cash | ₩24.24b |
| Equity | ₩248.62b |
| Total liabilities | ₩251.15b |
| Total assets | ₩499.78b |
Recent financial health updates
Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden
Apr 09
REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly
Jan 02
Recent updates
There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings
Mar 31Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend
May 08Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden
Apr 09What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?
Feb 28Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend
Jan 20REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly
Jan 02Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?
Dec 12How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?
Nov 24Financial Position Analysis
Short Term Liabilities: A102460's short term assets (₩99.8B) do not cover its short term liabilities (₩125.6B).
Long Term Liabilities: A102460's short term assets (₩99.8B) do not cover its long term liabilities (₩125.5B).
Debt to Equity History and Analysis
Debt Level: A102460's net debt to equity ratio (79.4%) is considered high.
Reducing Debt: A102460's debt to equity ratio has increased from 15.6% to 89.2% over the past 5 years.
Debt Coverage: A102460's debt is not well covered by operating cash flow (3.9%).
Interest Coverage: A102460 earns more interest than it pays, so coverage of interest payments is not a concern.